[{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 antiviral antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celltrion \/ Celltrion","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 antiviral antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"180 Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Celltrion","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Infliximab","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celltrion \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Abpro","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"ABP-102","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Celltrion","amount2":1.75,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.75,"dosageForm":"","sponsorNew":"Celltrion \/ Celltrion","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion \/ Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"LISCure Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Microbiome-based Therapy","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Celltrion","highestDevelopmentStatusID":"2","companyTruncated":"Celltrion \/ Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aaty","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celltrion \/ Rani Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion \/ Rani Therapeutics"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aaty","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Infliximab-dyyb","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Infliximab","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"CT-G20","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celltrion \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Infliximab","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANKL","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANKL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Celltrion

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Remdantry (infliximab) a TNF alpha inhibitor, is the first and only FDA-approved SC formulation, for adults with moderately to severely active ulcerative colitis and crohn’s disease.

                          Product Name : Remdantry

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 11, 2025

                          Lead Product(s) : Infliximab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Omlyclo (omalizumab) is an antibody inhibiting IgE binding. It is approved to treat chronic spontaneous urticaria & moderate to severe persistent asthma.

                          Product Name : Omlyclo

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 09, 2025

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Stoboclo (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia. It is a RANK ligand inhibitor, which is indicated for postmenopausal osteoporosis.

                          Product Name : Stoboclo

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Osenvelt (denosumab), referencing Xgeva, has been approved for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone)

                          Product Name : Osenvelt

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Avtozma (tocilizumab-biosimilar) is a recombinant humanized monoclonal antibody that acts as IL-6 receptor antagonist. It is indicated for moderate to severe active rheumatoid arthritis.

                          Product Name : Avtozma

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 23, 2025

                          Lead Product(s) : Tocilizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Eydenzelt (aflibercept) is a PGF & VEGF-A inhibitor, indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.

                          Product Name : Eydenzelt

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          February 18, 2025

                          Lead Product(s) : Aflibercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : FDA approvaed Avtozma, a biosimilar monoclonal antibody referencing Actemra, for moderate to severe active rheumatoid arthritis, systemic juvenile idiopathic arthritis, etc.

                          Product Name : Avtozma

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 31, 2025

                          Lead Product(s) : Tocilizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Steqeyma (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 17, 2024

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Omlyclo (omalizumab) is an antibody inhibiting IgE binding. It is approved to treat chronic spontaneous urticaria & moderate to severe persistent asthma.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 09, 2024

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Steqeyma (ustekinumab), a biosimilar to Stelara is an approved IL-12/IL-23 inhibitor indicated for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Steqeyma

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 25, 2024

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank